

Joanne L Jones

List of Publications by Citations

Source: <https://exaly.com/author-pdf/9562518/joanne-l-jones-publications-by-citations.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

57
papers

2,916
citations

25
h-index

54
g-index

66
ext. papers

3,605
ext. citations

8
avg, IF

4.74
L-index

#	Paper	IF	Citations
57	The window of therapeutic opportunity in multiple sclerosis: evidence from monoclonal antibody therapy. <i>Journal of Neurology</i> , 2006 , 253, 98-108	5.5	401
56	Lymphocyte homeostasis following therapeutic lymphocyte depletion in multiple sclerosis. <i>European Journal of Immunology</i> , 2005 , 35, 3332-42	6.1	248
55	IL-21 drives secondary autoimmunity in patients with multiple sclerosis, following therapeutic lymphocyte depletion with alemtuzumab (Campath-1H). <i>Journal of Clinical Investigation</i> , 2009 , 119, 2052-61	15.9	215
54	B-cell reconstitution and BAFF after alemtuzumab (Campath-1H) treatment of multiple sclerosis. <i>Journal of Clinical Immunology</i> , 2010 , 30, 99-105	5.7	180
53	Association of Initial Disease-Modifying Therapy With Later Conversion to Secondary Progressive Multiple Sclerosis. <i>JAMA - Journal of the American Medical Association</i> , 2019 , 321, 175-187	27.4	172
52	Alemtuzumab treatment of multiple sclerosis: long-term safety and efficacy. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2015 , 86, 208-15	5.5	164
51	Human autoimmunity after lymphocyte depletion is caused by homeostatic T-cell proliferation. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013 , 110, 20200-5	11.5	149
50	Long term lymphocyte reconstitution after alemtuzumab treatment of multiple sclerosis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2012 , 83, 298-304	5.5	148
49	Improvement in disability after alemtuzumab treatment of multiple sclerosis is associated with neuroprotective autoimmunity. <i>Brain</i> , 2010 , 133, 2232-47	11.2	131
48	Non-myeloablative autologous haematopoietic stem cell transplantation expands regulatory cells and depletes IL-17 producing mucosal-associated invariant T cells in multiple sclerosis. <i>Brain</i> , 2013 , 136, 2888-903	11.2	130
47	Immune competence after alemtuzumab treatment of multiple sclerosis. <i>Neurology</i> , 2013 , 81, 872-6	6.5	95
46	Distinct microbial and immune niches of the human colon. <i>Nature Immunology</i> , 2020 , 21, 343-353	19.1	92
45	Clinical relevance of serum antibodies to extracellular N-methyl-D-aspartate receptor epitopes. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2015 , 86, 708-13	5.5	81
44	Secondary autoimmune diseases following alemtuzumab therapy for multiple sclerosis. <i>Expert Review of Neurotherapeutics</i> , 2012 , 12, 335-41	4.3	65
43	A novel strategy to reduce the immunogenicity of biological therapies. <i>Journal of Immunology</i> , 2010 , 185, 763-8	5.3	58
42	Accelerated lymphocyte recovery after alemtuzumab does not predict multiple sclerosis activity. <i>Neurology</i> , 2014 , 82, 2158-64	6.5	44
41	Mode of action and clinical studies with alemtuzumab. <i>Experimental Neurology</i> , 2014 , 262 Pt A, 37-43	5.7	43

40	Alemtuzumab-Induced Thyroid Dysfunction Exhibits Distinctive Clinical and Immunological Features. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2018 , 103, 3010-3018	5.6	35
39	Predicting autoimmunity after alemtuzumab treatment of multiple sclerosis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2014 , 85, 795-8	5.5	34
38	Alemtuzumab use in neuromyelitis optica spectrum disorders: a brief case series. <i>Journal of Neurology</i> , 2016 , 263, 25-9	5.5	33
37	New treatment strategies in multiple sclerosis. <i>Experimental Neurology</i> , 2010 , 225, 34-9	5.7	31
36	Campath-1H treatment of multiple sclerosis. <i>Neurodegenerative Diseases</i> , 2008 , 5, 27-31	2.3	30
35	Peripheral innate immune and bacterial signals relate to clinical heterogeneity in Parkinson's disease. <i>Brain, Behavior, and Immunity</i> , 2020 , 87, 473-488	16.6	29
34	Neonatal and adult recent thymic emigrants produce IL-8 and express complement receptors CR1 and CR2. <i>JCI Insight</i> , 2017 , 2,	9.9	26
33	Hemophagocytic lymphohistiocytosis in 2 patients with multiple sclerosis treated with alemtuzumab. <i>Neurology</i> , 2018 , 90, 849-851	6.5	25
32	Discovery of CD80 and CD86 as recent activation markers on regulatory T cells by protein-RNA single-cell analysis. <i>Genome Medicine</i> , 2020 , 12, 55	14.4	24
31	Multiple sclerosis risk variants alter expression of co-stimulatory genes in B cells. <i>Brain</i> , 2018 , 141, 786-796	16.2	23
30	Radiologically compatible CLIPPERS may conceal a number of pathologies. <i>Brain</i> , 2011 , 134, e187	11.2	22
29	Monocyte Function in Parkinson's Disease and the Impact of Autologous Serum on Phagocytosis. <i>Frontiers in Neurology</i> , 2018 , 9, 870	4.1	22
28	Sarcoidosis following alemtuzumab treatment for multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2018 , 24, 1779-1782	5	21
27	2019 European Thyroid Association Guidelines on the Management of Thyroid Dysfunction following Immune Reconstitution Therapy. <i>European Thyroid Journal</i> , 2019 , 8, 173-185	4.2	20
26	Extracellular Lactate: A Novel Measure of T Cell Proliferation. <i>Journal of Immunology</i> , 2018 , 200, 1220-1226	5.5	17
25	Immunological considerations and challenges for regenerative cellular therapies. <i>Communications Biology</i> , 2021 , 4, 798	6.7	14
24	Cross-tissue immune cell analysis reveals tissue-specific features in humans. <i>Science</i> , 2022 , 376, eabl5197	33.3	13
23	Keratinocyte growth factor impairs human thymic recovery from lymphopenia. <i>JCI Insight</i> , 2019 , 5,	9.9	10

22	Cross-tissue immune cell analysis reveals tissue-specific adaptations and clonal architecture in humans		9
21	Neuroanatomical substrates of generalized brain dysfunction in COVID-19. <i>Intensive Care Medicine</i> , 2021 , 47, 116-118	14.5	7
20	Complex Autoantibody Responses Occur following Moderate to Severe Traumatic Brain Injury. <i>Journal of Immunology</i> , 2021 ,	5.3	6
19	Safety and efficacy of bexarotene in patients with relapsing-remitting multiple sclerosis (CCMR One): a randomised, double-blind, placebo-controlled, parallel-group, phase 2a study. <i>Lancet Neurology</i> , 2021 , 20, 709-720	24.1	6
18	Detection limit of Zr-labeled T cells for cellular tracking: an in vitro imaging approach using clinical PET/CT and PET/MRI. <i>EJNMMI Research</i> , 2020 , 10, 82	3.6	5
17	Periventricular magnetisation transfer ratio abnormalities in multiple sclerosis improve after alemtuzumab. <i>Multiple Sclerosis Journal</i> , 2020 , 26, 1093-1101	5	5
16	Transcript specific regulation of expression influences susceptibility to multiple sclerosis. <i>European Journal of Human Genetics</i> , 2020 , 28, 826-834	5.3	4
15	Imaging intralésional heterogeneity of sodium concentration in multiple sclerosis: Initial evidence from Na-MRI. <i>Journal of the Neurological Sciences</i> , 2018 , 387, 111-114	3.2	4
14	Increased THEMIS First Exon Usage in CD4+ T-Cells Is Associated with a Genotype that Is Protective against Multiple Sclerosis. <i>PLoS ONE</i> , 2016 , 11, e0158327	3.7	3
13	Severe paradoxical disease activation following alemtuzumab treatment for multiple sclerosis. <i>Neurology: Neuroimmunology and Neuroinflammation</i> , 2020 , 7,	9.1	2
12	Meeting abstracts from the 64th British Thyroid Association Annual Meeting. <i>Thyroid Research</i> , 2017 , 10,	2.4	2
11	The MS Remyelinating Drug Bexarotene (an RXR Agonist) Promotes Induction of Human Tregs and Suppresses Th17 Differentiation. <i>Frontiers in Immunology</i> , 2021 , 12, 712241	8.4	2
10	Acute posterior multifocal placoid pigment epitheliopathy after alemtuzumab treatment for relapsing-remitting multiple sclerosis. <i>Journal of Neurology</i> , 2019 , 266, 1539-1540	5.5	1
9	A case of anaphylaxis to alemtuzumab. <i>Journal of Neurology</i> , 2019 , 266, 780-781	5.5	1
8	Recent thymic emigrants produce antimicrobial IL-8, express complement receptors and are precursors of a tissue-homing Th8 lineage of memory cells		1
7	The MS remyelinating drug bexarotene (an RXR agonist) promotes induction of human Tregs and suppresses Th17 differentiation in vitro		1
6	Autoimmunity and long-term safety and efficacy of alemtuzumab for multiple sclerosis: Benefit/risk following review of trial and post-marketing data. <i>Multiple Sclerosis Journal</i> , 2021 , 13524585211061335	5.2	1
5	Therapeutically expanded human regulatory T-cells are super-suppressive due to HIF1A induced expression of CD73. <i>Communications Biology</i> , 2021 , 4, 1186	6.7	0

- 4 Progressive multifocal leucoencephalopathy with Behçet disease: an insight into pathophysiology. *Rheumatology*, **2017**, 56, 668-670 3.9 0
- 3 Targeting CD52 for the Treatment of Multiple Sclerosis **2013**, 385-399
- 2 The yin and yang of intracellular reactive oxygen species following T-cell activation. *Brain*, **2021**, 144, 2909-2911 11.2
- 1 The immunogenicity of midbrain dopaminergic neurons and the implications for neural grafting trials in Parkinson disease. *Neuronal Signaling*, **2021**, 5, NS20200083 3.7